169 results about "Antigenicity" patented technology

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.

The invention discloses a surface antigen gene StSAG1 of Sarcocystis tenella, the nucleotide sequence of the surface antigen gene StSAG1 is as shown in SEQ ID NO: 1, and according to the analysis result of protein antigenicity and antigen epitope, the 686 bp-1175 bp segment of the StSAG1 gene is selected to construct a recombinant protein expression vector and engineering bacteria; the antigen disclosed by the invention has very strong antigenicity and specificity, and can be subjected to effective antigen-antibody reaction with an antibody generated in serum after sheep (Ovis aries) is infected with sarcosporidium tenella, so that diagnosis is realized; low-titer antibodies can be detected two weeks after infection, and the detection window period is obviously advanced; by adopting the ELISA detection method, a visual result can be directly obtained. The method breaks through the limitation of an infection window period, has the advantages of low cost, high sensitivity, simplicity and convenience in operation, no need of expensive instruments and analysis and the like, is suitable for field detection in primary laboratories and pastures, and is beneficial to industrial production and market popularization and application.

The invention is applicable to the technical field of biology, and provides an L7 / L12-PADRE sequence-multi-linked B cell epitope recombinant protein and a kit for detecting an anti-Brucella antibody. The recombinant protein is a multi-epitope tandem recombinant protein composed of Brucella ribosome L7 / L12 protein, a PADRE polypeptide sequence and multiple B cell epitopes, the amino acid sequence of the recombinant protein is as shown in SEQ ID No.1, and the recombinant protein is good in antigenicity. The anti-brucella antibody indirect ELISA (iELISA) detection method and kit established by taking the recombinant protein as the coating antigen have the characteristics of high sensitivity, strong specificity and good repeatability, are suitable for detecting the condition of generating the anti-brucella antibody by an organism, can clarify the immune background of brucella infection or brucellosis vaccine, and can be used for detecting the brucella infection or brucellosis vaccine. Basic data is provided for prevention and control of the Brucella disease of humans and animals, and meanwhile, the kit is conveniently applied to large-scale sample detection and epidemiological monitoring.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

The invention provides a double-layer collagen scaffold repair membrane as well as a preparation method and application thereof, and the preparation method comprises the following steps: extracting collagen from animal fur, and emulsifying to obtain a collagen emulsion; adding a cross-linking agent into the collagen emulsion, and emulsifying to obtain a cross-linked protein emulsion; pouring the cross-linked protein emulsion into a mold, and freeze-drying to obtain a cross-linked protein layer; and pouring the collagen emulsion on the cross-linked protein layer, and freeze-drying to obtain the double-layer collagen scaffold repair membrane. The repairing membrane is excellent in structure, the cross-linked protein layer provides mechanical strength and supporting performance, the collagen layer can be rapidly dissolved and attached to the contact surface, and oxygen exchange and metabolite discharge of the wound surface are facilitated; the collagen is high in purity, low in antigenicity and high in safety, any toxic and harmful chemical reagents and preservatives are not added, allergy or inflammatory reaction is avoided, and the collagen has good application prospects in the fields of medical treatment, medical beauty, beauty, skin care and the like.

The invention, in some aspects, relates to compositions comprising modified viral nucleocapsid (N) proteins and their encoding polynucleotides and methods of using such compositions and preparations to increase viral N protein dimerization and / or increase antigenicity of viral immunization preparations.

The invention provides a medical absorbable collagen antibacterial suture line and a preparation method thereof. The preparation method comprises the following steps: S1, sequentially carrying out pretreatment, homogenization, digestion, sterilization, salting-out and purification on animal skin to obtain collagen; s2, performing solution blending on collagen and a chitosan derivative to prepare a spinning solution; s3, performing wet spinning on the spinning solution to obtain a wire rod; and S4, crosslinking or weaving the wire rod to prepare the medical antibacterial suture line capable of absorbing collagen. The suture line is high in collagen purity, in a special fiber bundle shape, low in antigenicity, good in spinnability, smooth in surface, soft and smooth in line body and easy to knot, does not need to be soaked before being used, can reduce scar hyperplasia and avoid centipede-shaped suture traces during suture, has antibacterial and hemostatic functions, and is suitable for clinical application. A physical hemostasis barrier can be quickly generated in the suturing process, and an excellent suturing effect is achieved.

This invention belongs to the field of biotechnology and discloses a dry film stabilizer, cytoplasmic antigen dry films, their preparation methods, and applications. The dry film stabilizer includes polyethylene glycol, trehalose, BSA, melatonin, and Tween-20. Cytoplasmic antigen dry films are prepared using this stabilizer and applied in CBA detection. This dry film stabilizer has good permeability, penetrating the cell membrane to enter the cell interior, providing protection both inside and outside the cell. It also possesses moisturizing and antioxidant properties, preventing cell deformation and shedding of the cell fixation layer, effectively maintaining the stability and reliability of intracellular antigen proteins. The prepared cytoplasmic antigen dry films can be stored long-term without damaging the antigenicity of cytoplasmic signal indicators. When detecting positive samples, strong and numerous green filamentous fluorescence signals are observed in the cytoplasm, with consistent green and red fluorescence intensities. Software synthesis reveals co-localization of green and red antigen fluorescence.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

The present invention relates to a platform concept for presenting antigenic polypeptides as part of a virus like particle (VLP) construct, which comprises a Gag (group-specific antigen) protein of a beta-retrovirus, for instance of a human endogenous retrovirus K (HERV-K) or of IAPE. Surprisingly it was found that antigenic polypeptide expression in a VLP comprising a Gag protein of HERV-K or of murine endogenous retrovirus IAPE (Intracisternal A-type Particles elements with an Envelope) promotes antigenic polypeptide display and immunogenicity.

Described herein are compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and a nucleic acid sequence (e.g., mRNA) encoding at least one universal T-cell epitope (UTE), as well as compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and at least one universal T-cell epitope, and methods for using the compositions.

The application provides a monoclonal antibody for specifically detecting rotavirus and an application thereof, and is directed to epidemic strains of porcine rotavirus, and refers to the gene sequence of VP6 protein published in GenBank, further optimizes an antigen epitope, obtains a purified recombinant VP6 protein with antigenicity, and performs animal immunization, and successfully screens the monoclonal antibody capable of specifically recognizing the porcine rotavirus. The monoclonal antibody screened can effectively recognize the epidemic strains, has the broad-spectrum recognition, is superior to the commercially available antibody, has high antigen recognition target specificity, is low in non-specificity, and has clear sequence background, can be scaled up and produced, and has good commercial value.

Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and / or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and / or in vaccine compositions.

The present invention relates to the definition of a pool of antigenic sperm peptides with high species specificity for regulating populations of water vole (Arvicola terrestris scherman) using a vaccine approach.

This invention belongs to the field of RNA biocontrol technology, specifically relating to the application of dsRNA targeting genes encoding antigenic sweet proteins. This invention provides the application of dsRNA targeting genes encoding antigenic sweet proteins in the control of crop anthracnose, wherein the dsRNA is encoded by a gene encoding an antigenic sweet protein. CsATLP1 The dsRNA was obtained by partial sequence transcription. By loading the above-mentioned dsRNA onto the nanomaterial layered double hydroxide, the pathogenicity of *Anthracnose rubrum* and *Anthracnose mango* can be significantly reduced, showing promising application prospects for efficient and targeted control of crop anthracnose.

A nucleic acid construct encoding multiple polypeptide antigens or immunogens, or other polypeptides of interest. The construct expresses a protein that includes immunogenic or antigenic sequences from two, three, or more polypeptides of interest. Once expressed by the nucleic acid construct, the protein is processed by cleavage of an N-terminal signal peptide and by cleavage of 6K, 6K-like, or internal signal peptide cleavage sites to release each polypeptide of interest.

The disclosures of the invention arc directed to the manufacture of effective, affordable vaccines that arc globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA CO VID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.l, BA.2, and BA.4 / BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.

The disclosure provides polypeptides that specifically bind to HLA-DQ8 for treating Type 1 Diabetes (TID) and methods using same for reducing autoimmune destruction of pancreatic islet beta cells. In particular, the present disclosure relates to peptides containing at least one D-amino acid that are capable of blocking the presentation of antigenic islet peptides (e.g., lnsB:9-23) by HLA-DQ8, and to their uses, especially as it relates to the prevention and / or treatment of TID.

To provide vaccines and methods.SOLUTION: Described herein are methods for identifying optimized antigenic pathogen polypeptides capable of inducing a broadly neutralizing immune response and associated T-cell responses to a pathogen, and nucleic acid sequences encoding such polypeptides. Also described are methods for determining whether a broadly neutralizing immune response is induced in a subject following immunization with an optimized antigenic pathogen polypeptide or a nucleic acid encoding the optimized pathogen polypeptide. Further described are nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, and their use as vaccines against pathogens, especially against emerging or re-emerging pathogens (particularly RNA viruses).SELECTED DRAWING: None

This invention discloses a multi-epitope virus-like particle antigen (VLP) of type O foot-and-mouth disease virus (FMDV), its preparation method, and its application. The type O FMDV VLP antigen is a recombinant antigen protein formed by sequentially tandemly connecting the antigenic epitopes of five representative strains of type O FMDV topotypes—O / Tibet / CHA / 99, O / Mya98 / BY / 2010, O / HN / CHA / 93, O / XJPS / CHA / 2017, and Cathay—with the SpyCather and bacteriophage AP205 genes, and then tandemly connecting them with the epitopes of the first four strains. This recombinant protein can self-assemble into a VLP antigen. Immunological experiments show that this VLP antigen has good antigenicity, and its antigenic reactivity with type O FMDV is not significantly different, making it a viable alternative to inactivated FMDV antigens in detection methods. Vaccines prepared using this VLP antigen not only induce high levels of protective antibodies but also protect immunized animals against viral challenge. Furthermore, it is not limited by animal species and provides immune protection against type O foot-and-mouth disease in pigs, cattle, and sheep.

Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.

A nucleic acid construct encoding a plurality of polypeptide antigens or immunogens or other polypeptides of interest. The constructs express proteins comprising immunogenic or antigenic sequences of two, three or more polypeptides of interest. Once expressed by the nucleic acid construct, the protein is processed by cleaving the N-terminal signal peptide and cleaving the 6K, 6K-like or internal signal peptide cleavage site to release each polypeptide of interest. Vectors comprising the constructs can be used to deliver them to subjects in need of vaccination, the vectors comprising a replicon and a live viral vector. Vaccines and methods of treatment using the nucleic acid constructs are also described.

The invention discloses preparation and application of a mouse TMC5 truncated recombinant protein and a polyclonal antibody, and belongs to the technical field of biological medicine. The amino acid sequence of the TMC5 truncated recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the TMC5 truncated recombinant protein is as shown in SEQ ID NO. 2. Compared with a full-length protein, the mouse TMC5 truncated recombinant protein provided by the invention has better stability and antigenicity, the obtained polyclonal antibody is high in titer and strong in specificity, the identification of endogenous TMC5 protein in mouse testicular tissues is facilitated, meanwhile, the TMC5 truncated recombinant protein and the polyclonal antibody can also be used for researching a mechanism of regulating spermatogenesis by TMC5, and the application prospect is broad. The blank of preparation of the mouse TMC5 antibody and functional research of the mouse TMC5 antibody in the testis is filled. The mouse TMC5 truncated recombinant protein and the polyclonal antibody can be applied to development of novel diagnostic reagents and drugs for treating male sterility.

The invention discloses a step-by-step enzymolysis method for alpha-lactalbumin allergic epitopes and application, and belongs to the technical field of dairy product processing. Through step-by-step directional enzymolysis of flavourzyme and alpha-chymotrypsin, allergic epitopes in ALA are directionally cleared, and the antigenicity of ALA is remarkably reduced. The method is simple and convenient in process, mild in condition and suitable for large-scale production, and the obtained enzymolysis product can be used for low-sensitization infant formula milk powder and food for special medical purposes and has important application value and social benefits.

The invention provides a polypeptide that is antigenic in a host. The invention also provides a vaccine for use in reducing or preventing Campylobacter colonization in a host. The vaccine comprises a polypeptide of the present invention and / or antibodies against the polypeptide of the present invention. The host may be a human, cow, sheep, goat, and chicken. The invention has particular application for reducing or preventing Campylobacter jejuni colonization in poultry. The invention also provides a vaccine for use in reducing or preventing campylobacteriosis; and a vaccine composition comprising the polypeptide of the present invention; or antibodies raised against the polypeptide of the present invention, in association with a pharmaceutically acceptable vehicle useful for inducing an immune response in a host.

The invention relates to the field of genetic engineering and biological medicine, in particular to an influenza A virus mutant strain and application thereof in preparation of vaccines, and the influenza A virus mutant strain is obtained by mutation of acetylation modification sites on hemagglutinin protein of influenza A H1N1 subtype viruses. The influenza A virus mutant strain can reduce the pathogenicity of the virus to mice without reducing the antigenicity of the virus, so that the pathogenicity of the virus to the mice through intrapulmonary inoculation is remarkably reduced, meanwhile, pathological changes of virus infection are not generated, but complete challenge protection can be provided for the mice, and therefore, the influenza A virus mutant strain can be used for preparing vaccines.

The invention provides a specific monoclonal antibody for detecting rotavirus and application of the specific monoclonal antibody, aiming at an epidemic strain of porcine rotavirus, reference to a gene sequence of VP6 protein published by GenBank, antigen epitopes are further optimized, and purified recombinant VP6 protein with antigenicity is obtained for animal immunization. The monoclonal antibody capable of specifically recognizing the porcine rotavirus is successfully screened out. The monoclonal antibody obtained through screening can effectively recognize epidemic strains, has broad-spectrum recognition, is superior to commercially available antibodies, and has high antigen recognition target performance and low non-specificity. And the sequence background is clear, large-scale amplification and production can be carried out, and the method has good commercial value.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.